Ratings on (NKTR) (NPSP) ( OTEX) (RNOW) (ROK) Reiterated

Ratings on Nektar Therapeutics (NASDAQ: NKTR), Nps Pharmaceuticals Incorporated (NASDAQ: NPSP), Open Text (NASDAQ: OTEX), RightNow Technologies (NASDAQ: RNOW) and Rockwell Automation Inc (NYSE: ROK) reiterated by analysts.

Deutsche Bank (NYSE:DB) reiterated a “buy” rating on Nektar Therapeutics (NKTR). They have a price target of $14 on the company.

Brean Murray reiterated a “buy” rating on Nps Pharmaceuticals Incorporated (NPSP).

Raymond James (NYSE:RJF) reiterated an “outperform” rating on Open Text (OTEX).

Morgan Stanley (NYSE:MS) reiterated an “equal weight” rating on shares of RightNow Technologies (RNOW).

JPMorgan Chase & Co. (NYSE:JPM) reiterated a “neutral” rating on shares of Rockwell Automation Inc (ROK).

NPS Pharmaceuticals' (Nasdaq:NPSP) Shares Explode on Gattex Study Results

Positive results for NPS Pharmaceuticals' (Nasdaq:NPSP) Gattex resulted in shares of the company soaring over 30 percent.

Gattex treats patients with short bowel syndrome, which reduces the amount of intravenous nutrition needed by patients with the condition. NPS specializes in therapeutics for gastrointestinal and endocrine disorders.

The late-stage study was successful, driving the share price of NPSP up.

NPS Pharmaceuticals closed Monday at $10.01, gaining $2.39, or 31.47 percent.

NPS Pharmaceuticals' (NASDAQ:NPSP) STEPS Success Would Give Strong Upside

Based on the probability of GATTEX Phase III success, Canaccord sees NPS Pharmaceuticals Inc. (NASDAQ:NPSP) getting a boost to $14 a share on that alone, and potentially much higher on pricing and expanded penetration.

Canaccord says, "Supported by our conviction in a successful STEPS Phase III trial, we remain buyers of NPSP shares ahead of data read-out expected later this quarter...Modeling GATTEX pricing at $65K per patient per year of chronic therapy and 15% penetration in 2015 supports our conservative $7 per share estimate contribution to our $11 price target. STEPS success would get us to $14 per share while higher pricing and penetration assumptions support significant upside potential."

Canaccord Genuity reiterates a "Buy" rating on NPS Pharmaceuticals Inc. (NPSP), which closed Wednesday at $7.59, dropping $0.64, or 7.78 percent. Canaccord has a price target of $11 on them.

NPS Pharmaceuticals (NASDAQ:NPSP) Gets Favorable Amgen/NPSP Ruling

The favorable outcome of the lawsuit by NPS Pharmaceuticals (NASDAQ:NPSP) against Teva for ANDA filing of generic Sensipar has been ruled in NPS's favor, and that removes significant risk for the company.

Brean Murray Carret & Co. said the ruling should keep the generic Sensipar off the market until 2018, when the original Sensipar patents run out.

They raised their full year 2010 and full year 2011 EPS estimates from $0.77 and $0.42 to $0.75 and $0.37.

Brean Murray Carret & Co. reiterates a "Buy" rating on NPS Pharmaceuticals Inc., which closed Monday at $7.61, gaining $0.39, or 5.4 percent. They increased their price target on NPS from $10 to $11.

Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS), Best Biotech Ideas for 2011

Within the small and mid-cap biotech sector, Canaccord Genuity named its best ideas for 2011, which include Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS Pharmaceuticals (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS) and NPS Pharmaceuticals (Nasdaq:NPSP).

Canaccord said, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."

Amarin: AMR101 had positive data from its first pivotal trial in patients with very triglycerides.

Amicus: Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.

Dendreon is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.

NPS Pharmaceuticals is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.

Orexigen: Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.

Pharmasset: Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.

Amarin closed Tuesday at $5.92, up $0.12, or 2.07 percent. Amicus closed at $4.01, up $0.03, or 0.75 percent. Dendreon ended at $36.28, down $0.28, or 0.77 percent. NPS Pharmaceuticals closed at $7.11, up $0.09, or 1.28 percent. Orexigen closed at $9.01, down $0.01, or 0.11 percent. Pharmasset was up to $47.19, gaining $0.42, or 0.90 percent.